Lupus Research Alliance logo
Targeted Research Program on Engineered Cell Therapies for Lupus

Targeted Research Program on Engineered Cell Therapies for Lupus

Runs CART and next-generation cell therapy development in lupus through the Targeted Research on Engineered Cell Therapies for.

ClosedLupus Research AllianceUnited States
View on funder site
About

The Targeted Research Program on Engineered Cell Therapies for Lupus is a dedicated grant mechanism of the Lupus Research Alliance (LRA) funding next-generation engineered cell therapy development with direct and clear relevance to people living with lupus. The LRA, a New York 501(c)(3) nonprofit (Federal Tax ID #58-2492929) with over $284 million awarded to 675+ grants, identified engineered cell…

What this grant funds

Next-generation engineered cell therapies for lupus, covering pre-clinical discovery and translational projects (up to $300K) or ancillary studies to ongoing or completed engineered cell therapy clinical trials (up to $600K).

Key facts
CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Annual
Next deadlineiThe next date applications are due. Rolling means you can apply any time.—
Decision timeiTypical time from the deadline to the funder's decision.—
Project durationiHow long the funded work is expected to run.24 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.—
Funding analytics

Sign up free to see the funding breakdown

Create free accountSign in
Industries

Sign up free to see the industries in scope

Create free accountSign in
Eligibility criteria

Sign up free to see the full eligibility

Create free accountSign in
Timeline

Sign up free to see the timeline

Create free accountSign in
Last verified: 24 Jul 2026Source: www.lupusresearch.org